Evaluation of Intranasal oxytocine spray effect on preventing post-dural puncture headache after cesarean section

Evaluation of Intranasal oxytocine spray effect on preventing post-dural puncture headache after elective cesarean section, A Clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201215049725N1

Enrollment

170

Registered

2021-09-10

Start date

2021-09-29

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

post-dural puncture headache. Spinal and epidural anesthesia-induced headache during the puerperium

Interventions

Intervention 1: Intervention group: After cesarean section, The intervention group is given 3-puff (30IU) nasal oxytocin (Alborz Drug Company, Made in Iran) as a single dose immediately after delivery

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Elective cesarean candidates

Exclusion criteria

Exclusion criteria: Allergies to drugs used in this study BMI more than 35 Hepatic, renal or cardiac disorder Neuromuscular disease History of lumbar discopathy / history of neuropathy Opioids or analgesic usage 3 days before the study Consumption of calcium channel blockers

Design outcomes

Primary

Measure	Time frame
Headache severity after spinal anesthesia based on vas-score. Timepoint: 12, 24, 48, 72 hours after cesarean section. Method of measurement: Visual Analogue Scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactBanafshe Mashak

Karaj University of Medical Sciences

banafshemashak@abzums.ac.ir+98 26 3222 3021

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026